Sanofi
SNY
643 hedge funds and large institutions have $12.7B invested in Sanofi in 2022 Q4 according to their latest regulatory filings, with 121 funds opening new positions, 203 increasing their positions, 206 reducing their positions, and 55 closing their positions.
120% more first-time investments, than exits
New positions opened: 121 | Existing positions closed: 55
119% more call options, than puts
Call options by funds: $145M | Put options by funds: $66.5M
33% more capital invested
Capital invested by funds: $9.61B → $12.7B (+$3.13B)
21% more funds holding in top 10
Funds holding in top 10: 14 → 17 (+3)
10% more funds holding
Funds holding: 587 → 643 (+56)
0.58% more ownership
Funds ownership: 20.12% → 20.69% (+0.58%)
1% less repeat investments, than reductions
Existing positions increased: 203 | Existing positions reduced: 206
Top Buyers
| 1 |
Dodge & Cox
San Francisco,
California
|
+$375M |
| 2 |
Bank of New York Mellon
New York
|
+$108M |
| 3 |
N
Nuveen
Charlotte,
North Carolina
|
+$90.9M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
+$82.7M |
| 5 |
Millennium Management
New York
|
+$76.2M |
Top Sellers
SNY Hedge Fund Activity: Q4 2022 in Review
643 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Sanofi (SNY) for Q4 2022, worth a combined $12.7B — up 33% from $9.61B a quarter earlier.
Buyers outnumbered sellers: 121 funds opened new SNY positions and 55 closed out — a net gain of 66 holders — while 203 added to existing stakes and 206 trimmed.
The largest buyer was Dodge & Cox, adding an estimated $375M. The largest seller was T. Rowe Price Associates, cutting an estimated $413M.
- 643 institutional investors held Sanofi (SNY) as of Q4 2022, up from 587 in Q3 2022.
- Funds reported $12.7B of Sanofi stock for Q4 2022, up 33% quarter-over-quarter.
- 121 funds opened new Sanofi positions in Q4 2022 and 55 closed out, a net change of +66 holders.
- The largest Sanofi buyer in Q4 2022 was Dodge & Cox, an estimated $375M added.
- The largest Sanofi seller in Q4 2022 was T. Rowe Price Associates, an estimated $413M sold.
Based on aggregated 13F filings for Q4 2022.